Entresto

ApprovedSmall molecule

Novartis

Entresto is one of 115 small molecule programs targeting Peripheral Arterial Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Arterial DiseaseActive, not recruiting

HypertensionActive, not recruiting

Heart FailureActive, not recruiting

Type 2 DiabetesActive, not recruiting

Peripheral Arterial DiseasePhase 2

Active, not recruiting

HypertensionPreclinical

Active, not recruiting

Heart FailureApproved

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Entresto

Novartis

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Cysteine Hydrochloride

Novartis

Preclinical

1 6

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 8

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Acipimox

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fasting Conditions3 trials

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Unknown status· Viatris logo

Viatris·Phase 1·NCT06273254·48 enrolled

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Unknown status·—·Phase 1·NCT06193187·48 enrolled

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

Unknown status· Viatris logo

Viatris·Phase 1·NCT06266988·48 enrolled

Heart Failure2 trials

Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT03821701·340 enrolled

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

Completed·MMayo Clinic·Phase 4·NCT03506412·40 enrolled

Hypertensive2 trials

Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD

Withdrawn·UUniversity of Maryland, Baltimore·Phase 4·NCT03279861

Role of ARNi in Ventricular Remodeling in Hypertensive LVH

Completed·NNational Heart Centre Singapore·Phase 2·NCT03553810·80 enrolled

Echocardiography1 trial

Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis

Completed·UUniversity of Chicago·Phase 4·NCT02754518·40 enrolled

Hypertension1 trial

Special Drug Use Surveillance of Entresto Tablets (Hypertension)

Completed· Novartis logo

Novartis··NCT05976230·1,125 enrolled

5 more indications

Drug1 trial

Special Drug Use Surveillance for Entresto Tablets

Completed· Novartis logo

Novartis··NCT04781881·688 enrolled

Type 2 Diabetes1 trial

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

Completed·UUniversity of Copenhagen·Phase 4·NCT03893526·12 enrolled

Peripheral Arterial Disease1 trial

Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease

Terminated·UUniversity of Minnesota·Phase 2·NCT02636283·6 enrolled

Treatment1 trial

Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment

Unknown status·—··NCT03359967·24 enrolled

Unspecified1 trial

The Effects of Neprilysin on Glucagon-like Peptide-1

Completed·NNicolai Jacob Wewer Albrechtsen·Phase 4·NCT03717688·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Entresto. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Entresto compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Entresto. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Entresto

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Fasting Conditions3 trials

Heart Failure2 trials

Hypertensive2 trials

Echocardiography1 trial

Hypertension1 trial

Drug1 trial

Type 2 Diabetes1 trial

Peripheral Arterial Disease1 trial

Treatment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News